Skip to Main Content

As promised, President Trump has promptly abandoned the Trans-Pacific Partnership. What might this mean for biopharma?

Nixing the so-called TPP could spell trouble for the biopharmaceutical industry moving forward when it comes to market exclusivity, according to Kevin Noonan, a partner at Chicago-based intellectual property law firm McDonnell Boehnen Hulbert & Berghoff.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED